Receives FDA Clearance to Market its EksoNR™

NASDAQ:EKSO   Ekso Bionics Holdings, Inc
Ekso Bionics® Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Acquired Brain Injury Patients
announced it has received 501(k) clearance from the U.S. FDA to market its EksoNRTM robotic exoskeleton for use with patients with acquired brain injury ( ABI ).
EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI , significantly expanding the device’s indication to a broader group of patients.

Ekso , based in Richmond, California, had a net loss of $2.5 million in its latest quarter, narrower than the loss of $6.6 million posted in the year-earlier period. Revenue came to $1.5 million, down from $3.6 million, as the pandemic led some customers to delay orders.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.